Veru Advances Enobosarm Program with FDA Clarity in Obesity
MIAMI, Fla., December 17, 2025 — Veru Inc., a late-stage biopharmaceutical company, reported its fiscal year 2025 financial results...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MIAMI, Fla., December 17, 2025 — Veru Inc., a late-stage biopharmaceutical company, reported its fiscal year 2025 financial results...
CAMBRIDGE, Massachusetts, December 17, 2025 — uBriGene, a leader in advanced biopharmaceutical manufacturing, has launched LVV Turbo™, its next-generation...
